Category Archives: MS Treatment

-1 of 2- 29 May 2013 05:26:00 UTC PRESS RELEASE: World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease Novartis International AG / World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. -- New campaign 'MS and:Our Story' announced today, providing MS community with platform to share experiences of life with MS -- Launch of new Novartis social media platforms to help generate dialogue, information and experience exchange amongst MS community -- Novartis offices around the world undertake initiatives to support the MS community Basel, May 29, 2013 - Today Novartis is joining the global multiple sclerosis (MS) community in celebration of World MS Day by launching a new campaign and participating in initiatives that encourage information and experience exchange around MS. Novartis is committed to supporting the MS community through these initiatives, in addition to delivering and researching innovative treatments to help address the high unmet medical needs of people with MS … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing a patient specific T-cell immunotherapy for multiple sclerosis (MS), today honored World MS Day with a renewed commitment to the multiple sclerosis community. Opexa will be sponsoring a booth and will be presenting baseline data from its Immune Monitoring Program in a poster session at the 2013 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) & the Fifth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) May 29 June 1 in Orlando, Florida. Since May 2009, the Multiple Sclerosis International Federation (MSIF) has organized a World Multiple Sclerosis Day and this year it is being celebrated on May 29th. The purpose of this day is to raise global awareness of MS and how it impacts the lives of those living with the disease and their families. Multiple Sclerosis affects over 2 million people worldwide. Although much progress has been made in the development of new drugs to treat the Relapsing Remitting form of MS over the past several years, unfortunately, side effects continue to be a concern to many patients. Additionally, while Secondary Progressive MS affects approximately 35% of all people … Continue reading →

Basel, May 29, 2013 - Today Novartis is joining the global multiple sclerosis (MS) community in celebration of World MS Day by launching a new campaign and participating in initiatives that encourage information and experience exchange around MS. Novartis is committed to supporting the MS community through these initiatives, in addition to delivering and researching innovative treatments to help address the high unmet medical needs of people with MS at every stage of the disease. World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS and its impact on approximately 2.5 million people with MS around the world[1],[2]. This year`s World MS Day campaign focuses on young people; MS is normally diagnosed between the ages of 20 and 40[3], but can also occur earlier in life. This diagnosis can be devastating at a time when young people may be starting careers and making plans for the future. "Novartis proudly supports World MS Day, and we recognize and support the importance of creating dialogue amongst people with MS and the wider community to help create an environment of understanding," said David Epstein, Head of the Pharmaceuticals Division of Novartis Pharma AG. … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), together with the global multiple sclerosis (MS) community of patients, advocates and healthcare providers, will today celebrate World MS Day, a campaign created by the Multiple Sclerosis International Federation (MSIF) to raise awareness of MS. Genzyme is committed to making a difference in the lives of people living with MS with differentiated therapies that include once-daily, oral AUBAGIO and LEMTRADA, as well as a research pipeline focused on innovative approaches to treating MS. LEMTRADA (alemtuzumab) is currently under regulatory review. As aproud supporter of World MS Day and other MSIF programs, Genzyme has diversified its franchise offering with innovative grants and partnerships designed to broaden awareness about MS and address remaining unmet needs within the community. 2013 grants and partnerships include: The International Progressive MS Collaborative: Genzyme is an active supporter for this global platform, developed to leverage the unique expertise and resources of its experts to expedite the development of effective disease modifying and symptom management therapies for progressive forms of MS. MSIF Infrastructure Grant: Genzyme has provided a grant to the MSIF that will initiate, support and encourage the development of new MS organizations in Middle … Continue reading →

29 May 2013 Last updated at 19:28 ET By Eleanor Bradford BBC Scotland Health Correspondent Scotland is to benefit from a dedicated centre to test potential new treatments for multiple sclerosis. The MS trials unit at the Southern General in Glasgow will conduct clinical trials of drugs which could delay the progression of the condition. Scotland has the highest incidence of MS in the world, which makes it a top destination for drugs companies who want to test new treatments. Experts say the unit will help bring more lab-based research to the market. Consultant neurologist, Dr James Overell, who will work in the new unit, said: "This is a very exciting time in MS research. "I can diagnose up to five people a week with the condition. "Their main concern often is not always for the here and now, but what will happen to them later in life. Will they be in a wheelchair by the time they are 50? The unit will be able to give patients access to experimental treatments first and faster." Susanne McLean was diagnosed with MS shortly after she turned 30. "I finally got my diagnosis after about four years of different little symptoms cropping … Continue reading →

WESTON, Mass.--(BUSINESS WIRE)-- Biogen Idec (BIIB) joins the global multiple sclerosis (MS) community today to acknowledge the fifth annual World MS Day by hosting awareness and educational activities around the globe. Created by the Multiple Sclerosis International Federation (MSIF) and its member MS societies, World MS Day (http://mymotto.worldmsday.org/en) is a global awareness-raising campaign that informs the public about the intricacies of MS and its impact on the lives of more than two million people worldwide. Our decades-long partnership with the global MS community has helped to bring people with MS across the globe significant advances in treatment options, patient care and continued research advances. On World MS Day, we join together to build understanding and awareness of MS and reiterate our unwavering commitment to advance the fight against this debilitating disease, said John Richert, M.D., vice president, global medical affairs, Biogen Idec. We are working diligently to address the needs of people living with MS, bringing them new hope with the goal of improving their quality of life. This years theme for World MS Day is Young People with MS, focusing on six inspiring young people with MS and their personal mottos for relationships, their futures, and their identities. We … Continue reading →

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), being held in Orlando, FL, May 29 June 1. AMPYRA is an FDA-approved therapy indicated to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The results of the STEADY study being presented at CMSC expand our understanding of how AMPYRA may improve various dimensions of walking in people with MS and guide us towards endpoints for future studies, said Adrian Rabinowicz, M.D., FAAN, Acordas Senior Vice President of Clinical Development and Medical Affairs. We are sponsoring a range of studies aimed at exploring the use of AMPYRA within MS even as we look to potentially expand its use into post-stroke deficits and continue to develop other drugs in our pipeline such as rHIgM22 in MS, GGF2 in heart failure, and Diazepam Nasal Spray for treatment of certain epileptic seizures. Data being presented on AMPYRA at the CMSC annual meeting include: More detailed information on scientific sessions … Continue reading →

Justice Minister Judith Collins is being accused of "rorting the process" when she appointed National MP Jackie Blue as Equal Employment Opportunities Commissioner. Labour's Grant Robertson says the position was advertised and the closing date for expressions of interest closed on October 13 last year. The paper trail shows Ms Collins received a list of those who had applied on November 1, and Ms Blue's name wasn't on it. Her expression of interest was sent to the ministry on November 11, and a new list of candidates was sent to Ms Collins. "This appointment wasn't fair. Other candidates were not treated the same as Jackie Blue," Mr Robertson said on Tuesday. He questioned Ms Collins in parliament, and the minister said she received an informal expression of interest from Ms Blue on September 20. Ms Collins says she sent Ms Blue's formal expression of interest to the ministry herself on November 11. "Expressions of interest for a ministerial appointment close when the minister is satisfied they can make the right recommendation," she said. Mr Robertson says there's no evidence in the paper trail of an informal expression of interest on September 20. "In fact Ms Collins originally said in answer … Continue reading →

As the Wild's most experienced goaltender signed to a contract for next season, Josh Harding is strictly focused this summer on getting ready for next season. (Tim Fuller-USA TODAY Sports) Harding, diagnosed with multiple sclerosis late last summer, worked to get into shape to start this season on Minnesota's roster. A midseason change in medication forced him to the injured reserve list for nearly three months. All the time missed, as Harding and the doctors worked on finding the right treatment so he can keep playing, was all so he didn't have to worry about his illness any longer. As the Wild's most experienced goaltender signed to a contract for next season, Harding is focused this summer on getting ready for next season, not fighting MS. "That's why I missed time this year and the playoffs," Harding said after the season ended. "It obviously was a big curve ball thrown at myself. It took a lot of learning to cope with it and get the medications right. It did take a while; (I'm) definitely happy with where I am right now and we'll be even more dialed in next year." Harding, who turns 29 in June, has been Niklas Backstrom's … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing TcelnaTM, a patient specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced it will visit the NASDAQ MarketSite to ring the Closing Bell on Tuesday, May 28, 2013, at 4:00 pm EDT. In honor of World MS Day, Opexa's President and Chief Executive Officer, Neil K. Warma, joined by other members of the Opexa team, will ring the Closing Bell. We are very pleased to be invited to ring the Closing Bell on the eve of World MS Day, commented Mr. Warma. World MS Day will be celebrated this year on May 29th and was developed in 2009 by the Multiple Sclerosis International Federation (MSIF) to raise global awareness of MS and how it affects more than 2 million people worldwide. At Opexa, we are committed to the MS community and to the development of TcelnaTM, a novel immunotherapy for the treatment of Secondary Progressive MS. In addition, we are pleased to be associated with the NASDAQ Stock Market as it is through them that we gain access to those investors who support research and development in novel therapies for medical disorders with high unmet … Continue reading →